HIV Reservoir Reduction With Chidamide and CAR-NK Cell Therapy
Part of Immune system & allergy, Infections clinical trials.
This early-stage trial tests a combination of two treatments—a drug called chidamide and specially engineered immune cells (CAR-NK cells)—to reduce the hidden HIV reservoir in your body. The goal is to help control HIV infection more effectively, even while on standard antiretroviral therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- HIV diagnosis with at least 2 years of continuous antiretroviral therapy (HIV medications)
- Undetectable viral load: fewer than 50 copies of HIV per milliliter of blood
- CD4 count above 200 cells per microliter (a key immune cell count)
- Blood counts and liver/kidney function within acceptable ranges
- Heart function stable with ejection fraction of 45% or higher
- No active infections, cancers, or serious health conditions beyond controlled HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
This trial tests a new combination of drugs (chidamide, an anti-PD-1 antibody, and pegaspargase) against a standard treatment for people with advanced-stage, newly diagnosed NK/T-cell lymphoma. It aims to see if the new combination works better and is safe.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
This study tests whether combining immune checkpoint inhibitors with chidamide can help achieve a functional cure for HIV. It is for people living with HIV who are already on effective antiretroviral therapy and have a stable, well-controlled viral load.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.